167 related articles for article (PubMed ID: 26816205)
1. Health Services Utilization and Payments in Patients With Cancer Pain: A Comparison of Intrathecal Drug Delivery vs. Conventional Medical Management.
Stearns LJ; Hinnenthal JA; Hammond K; Berryman E; Janjan NA
Neuromodulation; 2016 Feb; 19(2):196-205. PubMed ID: 26816205
[TBL] [Abstract][Full Text] [Related]
2. Medical cost impact of intrathecal drug delivery for noncancer pain.
Guillemette S; Witzke S; Leier J; Hinnenthal J; Prager JP
Pain Med; 2013 Apr; 14(4):504-15. PubMed ID: 23480485
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Health Care Utilization and Cost of Targeted Drug Delivery and Conventional Medical Management vs Conventional Medical Management Alone for Patients With Cancer-Related Pain.
Stearns LJ; Narang S; Albright RE; Hammond K; Xia Y; Richter HB; Paramanandam GK; Haagenson KK; Doth AH
JAMA Netw Open; 2019 Apr; 2(4):e191549. PubMed ID: 30951156
[TBL] [Abstract][Full Text] [Related]
4. Longevity and cost of implantable intrathecal drug delivery systems for chronic pain management: a retrospective analysis of 365 patients.
Bolash R; Udeh B; Saweris Y; Guirguis M; Dalton JE; Makarova N; Mekhail N
Neuromodulation; 2015 Feb; 18(2):150-5; discussion 155-6. PubMed ID: 25250852
[TBL] [Abstract][Full Text] [Related]
5. A cost utilization analysis of intrathecal therapy for refractory cancer pain: identifying factors associated with cost benefit.
Brogan SE; Winter NB; Abiodun A; Safarpour R
Pain Med; 2013 Apr; 14(4):478-86. PubMed ID: 23461787
[TBL] [Abstract][Full Text] [Related]
6. Retrospective Analysis of Intrathecal Drug Delivery: Outcomes, Efficacy, and Risk for Cancer-Related Pain at a High Volume Academic Medical Center.
Sayed D; Monroe F; Orr WN; Phadnis M; Khan TW; Braun E; Manion S; Nicol A
Neuromodulation; 2018 Oct; 21(7):660-663. PubMed ID: 29446171
[TBL] [Abstract][Full Text] [Related]
7. Myth and Truth in Opioid Consumption with Intrathecal Morphine Pump Implantation in Chronic Pain: A Retrospective Cohort Study with Claims Database in South Korea.
Yoo Y; Oh JH; Lee H; Choi H; Joo S; Han AH; Moon JY
Pain Med; 2023 Jan; 24(1):79-88. PubMed ID: 35881702
[TBL] [Abstract][Full Text] [Related]
8. Infectious complications related to intrathecal drug delivery system and spinal cord stimulator system implantations at a comprehensive cancer pain center.
Engle MP; Vinh BP; Harun N; Koyyalagunta D
Pain Physician; 2013; 16(3):251-7. PubMed ID: 23703411
[TBL] [Abstract][Full Text] [Related]
9. Implantable drug delivery systems (IDDS) after failure of comprehensive medical management (CMM) can palliate symptoms in the most refractory cancer pain patients.
Smith TJ; Coyne PJ
J Palliat Med; 2005 Aug; 8(4):736-42. PubMed ID: 16128647
[TBL] [Abstract][Full Text] [Related]
10. Audit of intrathecal drug delivery for patients with difficult-to-control cancer pain shows a sustained reduction in pain severity scores over a 6-month period.
Mitchell A; McGhie J; Owen M; McGinn G
Palliat Med; 2015 Jun; 29(6):554-63. PubMed ID: 25690600
[TBL] [Abstract][Full Text] [Related]
11. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival.
Smith TJ; Staats PS; Deer T; Stearns LJ; Rauck RL; Boortz-Marx RL; Buchser E; Català E; Bryce DA; Coyne PJ; Pool GE;
J Clin Oncol; 2002 Oct; 20(19):4040-9. PubMed ID: 12351602
[TBL] [Abstract][Full Text] [Related]
12. Factors that might impact intrathecal drug delivery (IDD) dose escalation: a longitudinal study.
Mekhail N; Mahboobi R; Farajzadeh Deroee A; Costandi S; Dalton J; Guirguis M; Mehta P
Pain Pract; 2014 Apr; 14(4):301-8. PubMed ID: 23803173
[TBL] [Abstract][Full Text] [Related]
13. Intrathecal therapy for cancer and non-cancer pain.
Hayek SM; Deer TR; Pope JE; Panchal SJ; Patel VB
Pain Physician; 2011; 14(3):219-48. PubMed ID: 21587327
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain.
Deer TR; Smith HS; Burton AW; Pope JE; Doleys DM; Levy RM; Staats PS; Wallace MS; Webster LR; Rauck RL; Cousins M;
Pain Physician; 2011; 14(3):E283-312. PubMed ID: 21587338
[TBL] [Abstract][Full Text] [Related]
15. Intrathecal Drug Delivery Systems for Refractory Pancreatic Cancer Pain: Observational Follow-up Study Over an 11-Year Period in a Comprehensive Cancer Center.
Carvajal G; Dupoiron D; Seegers V; Lebrec N; Boré F; Dubois PY; Leblanc D; Delorme T; Jubier-Hamon S
Anesth Analg; 2018 Jun; 126(6):2038-2046. PubMed ID: 29543644
[TBL] [Abstract][Full Text] [Related]
16. Intrathecal Morphine Infusion Therapy in Management of Chronic Pain: Present and Future Implementation in Korea.
Kim EJ; Moon JY; Kim YC; Park KS; Yoo YJ
Yonsei Med J; 2016 Mar; 57(2):475-81. PubMed ID: 26847303
[TBL] [Abstract][Full Text] [Related]
17. Surgical Site Infections in Cancer Patients with Intrathecal Drug Delivery Devices.
Scanlon MM; Gazelka HM; Moeschler SM; Hoelzer BC; Hooten WM; Bendel MA; Lamer TJ
Pain Med; 2017 Mar; 18(3):520-525. PubMed ID: 27550951
[TBL] [Abstract][Full Text] [Related]
18. Systematic review of intrathecal infusion systems for long-term management of chronic non-cancer pain.
Patel VB; Manchikanti L; Singh V; Schultz DM; Hayek SM; Smith HS
Pain Physician; 2009; 12(2):345-60. PubMed ID: 19305484
[TBL] [Abstract][Full Text] [Related]
19. A post-market, randomized, controlled, prospective study evaluating intrathecal pain medication versus conventional medical management in the non-cancer, refractory, chronic pain population (PROSPER).
Pope JE; Jassal N; Sayed D; Patterson D; McDowell G; Bux A; Lim P; Chang E; Nairizi A; Grodofsky S; Deer TR
Expert Rev Med Devices; 2022 Nov; 19(11):895-904. PubMed ID: 36440473
[TBL] [Abstract][Full Text] [Related]
20. Advances in intrathecal drug delivery.
Lawson EF; Wallace MS
Curr Opin Anaesthesiol; 2012 Oct; 25(5):572-6. PubMed ID: 22825049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
